These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 16221792)

  • 1. Treatment of HBeAg-positive hepatitis B with peginterferon and lamivudine.
    Song K; Rajvanshi P
    N Engl J Med; 2005 Oct; 353(15):1630-1; author reply 1630-1. PubMed ID: 16221792
    [No Abstract]   [Full Text] [Related]  

  • 2. Peginterferon and lamivudine for hepatitis B.
    Assy NN; Hussein O
    N Engl J Med; 2004 Dec; 351(27):2879; author reply 2879. PubMed ID: 15625344
    [No Abstract]   [Full Text] [Related]  

  • 3. Does the addition of lamivudine to peginterferon alpha-2a sustain response rates in HBeAg-negative hepatitis B?
    Cooksley G
    Nat Clin Pract Gastroenterol Hepatol; 2005 Jan; 2(1):12-3. PubMed ID: 16265091
    [No Abstract]   [Full Text] [Related]  

  • 4. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
    Marcellin P; Lau GK; Bonino F; Farci P; Hadziyannis S; Jin R; Lu ZM; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Button P; Pluck N;
    N Engl J Med; 2004 Sep; 351(12):1206-17. PubMed ID: 15371578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interferon therapy for chronic hepatitis B].
    Tang WL; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):726-9. PubMed ID: 19874685
    [No Abstract]   [Full Text] [Related]  

  • 7. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.
    Bonino F; Marcellin P; Lau GK; Hadziyannis S; Jin R; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Brunetto MR; Farci P; Popescu M; McCloud P;
    Gut; 2007 May; 56(5):699-705. PubMed ID: 17127704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of HBeAg-positive hepatitis B with peginterferon and lamivudine.
    Orlent H
    N Engl J Med; 2005 Oct; 353(15):1630-1; author reply 1630-1. PubMed ID: 16224825
    [No Abstract]   [Full Text] [Related]  

  • 9. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.
    Fried MW; Piratvisuth T; Lau GK; Marcellin P; Chow WC; Cooksley G; Luo KX; Paik SW; Liaw YF; Button P; Popescu M
    Hepatology; 2008 Feb; 47(2):428-34. PubMed ID: 18220290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with interferons (including pegylated interferons) in patients with hepatitis B.
    Cooksley WG
    Semin Liver Dis; 2004; 24 Suppl 1():45-53. PubMed ID: 15192801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of lamivudine and interferon-alpha combination therapy on chronic hepatitis B].
    Tang Y; Chen G; Zheng R
    Zhonghua Gan Zang Bing Za Zhi; 2002 Apr; 10(2):89. PubMed ID: 11983118
    [No Abstract]   [Full Text] [Related]  

  • 12. Relapse after treatment with peginterferon alpha-2b alone or in combination with lamivudine in HBeAg positive chronic hepatitis B.
    Flink HJ; Buster EH; Merican I; Nevens F; Kitis G; Cianciara J; de Vries RA; Hansen BE; Schalm SW; Janssen HL
    Gut; 2007 Oct; 56(10):1485-6. PubMed ID: 17872587
    [No Abstract]   [Full Text] [Related]  

  • 13. Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study.
    Papadopoulos VP; Chrysagis DN; Protopapas AN; Goulis IG; Dimitriadis GT; Mimidis KP
    Med Sci Monit; 2009 Feb; 15(2):CR56-61. PubMed ID: 19179968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The maze of treatments for hepatitis B.
    Lok AS
    N Engl J Med; 2005 Jun; 352(26):2743-6. PubMed ID: 15987924
    [No Abstract]   [Full Text] [Related]  

  • 15. To genotype or not to genotype: toward an optimal tailoring of treatment of chronic hepatitis B.
    Lin CL; Kao JH
    Clin Infect Dis; 2007 Jun; 44(12):1665-6. PubMed ID: 17516416
    [No Abstract]   [Full Text] [Related]  

  • 16. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
    Gish RG; Lau DT; Schmid P; Perrillo R
    Am J Gastroenterol; 2007 Dec; 102(12):2718-23. PubMed ID: 17662102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiviral treatment of HBeAg positive chronic hepatitis B].
    Wang GQ
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):540. PubMed ID: 16042897
    [No Abstract]   [Full Text] [Related]  

  • 18. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B.
    Chan HL; Wong VW; Chim AM; Choi PC; Chan HY; Hui AY; Wong GL; Sung JJ
    Antivir Ther; 2007; 12(5):815-23. PubMed ID: 17713165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A reduction study of seroconversion of HBsAg in chronic hepatitis B patients with HBeAg positive by combination treatment with interferon and lamivudine].
    Yu SL; Qin LY; Wang C; Yu LJ; Guo CY; Wang YZ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):472-3. PubMed ID: 19567034
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.